Genetic Testing for Dilated Cardiomyopathy

Number 12.04.114

Effective Date March 10, 2014

Revision Date(s) N/A

Replaces 2.04.14


Genetic testing for dilated cardiomyopathy is considered investigational in all situations.

Related Policies


Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy


Genetic Testing for Congenital Long QT Syndrome

Policy Guidelines

There are several listings of genetic tests performed for dilated cardiomyopathy in the CPT Tier 2 molecular pathology codes listed below:





Molecular pathology procedure, Level 4 (e.g., analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons)

  • PLN: (phospholamban) (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy), full gene sequence


Molecular pathology procedure, Level 6 (e.g., analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis)

  • ANKRD1: (ankyrin repeat domain 1) (e.g., dilated cardiomyopathy), full gene sequence
  • TPM1: (tropomyosin 1 [alpha]) (e.g., familial hypertrophic cardiomyopathy), full gene sequence
  • TNNC1: (troponin C type 1 [slow]) (e.g., hypertrophic cardiomyopathy or dilated cardiomyopathy), full gene sequence


Molecular pathology procedure, Level 7 (e.g., analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia)

  • LDB3: (LIM domain binding 3) (e.g., familial dilated cardiomyopathy, myofibrillar myopathy), full gene sequence
  • LMNA: (lamin A/C) (e.g., Emery-Dreifuss muscular dystrophy [EDMD1, 2 and 3] limb-girdle muscular dystrophy [LGMD] type 1B, dilated cardiomyopathy [CMD1A], familial partial lipodystrophy [FPLD2]), full gene sequence
  • TNNT2: (troponin T, type 2 [cardiac]) (e.g., familial hypertrophic cardiomyopathy), full gene sequence


Molecular pathology procedure, Level 8 (e.g., analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform)

  • MYH6: (myosin, heavy chain 6, cardiac muscle, alpha) (e.g., familial dilated cardiomyopathy), full gene sequence
  • MYH7: (myosin, heavy chain 7, cardiac muscle, beta) (e.g., familial hypertrophic cardiomyopathy, Liang distal myopathy), full gene sequence
  • SCN5A: (sodium channel, voltage-gated, type V, alpha subunit) (e.g., familial dilated cardiomyopathy), full gene sequence


Dilated cardiomyopathy (DCM) is characterized by progressive left ventricular enlargement and systolic dysfunction, leading to clinical manifestations of heart failure. There are a variety of causes of DCM, which include genetic and nongenetic conditions. Genetic forms of DCM are heterogeneous in their molecular basis and clinical expression. Genetic testing for DCM has potential utility in confirming a diagnosis of genetic DCM, and as a predictive test in family members when familial DCM is present.


Dilated cardiomyopathy (DCM) is defined as the presence of left ventricular enlargement and dilatation in conjunction with significant systolic dysfunction. Dilated cardiomyopathy has an estimated prevalence of 1 in 2700 in the U.S.(1) The age of onset for DCM is variable, ranging from infancy to the eighth decade, with the majority of individuals developing symptoms in the fourth through sixth decade.(2)

The primary clinical manifestations of DCM are heart failure and arrhythmias. Symptoms of heart failure, such as dyspnea on exertion and peripheral edema, are the most common presentation of DCM. These symptoms are generally gradual in onset and slowly progressive over time. Progressive myocardial dysfunction may also lead to electrical instability and arrhythmias. Symptoms of arrhythmias may include light-headedness, syncope or sudden cardiac arrest.

There are many underlying conditions that can cause DCM, including(3):

  • Ischemic coronary artery disease
  • Toxins
  • Metabolic conditions
  • Endocrine disorders
  • Inflammatory and infectious diseases
  • Infiltrative disorders
  • Tachycardia-mediated cardiomyopathy

Therefore, when a patient presents with DCM, a workup is performed to identify underlying causes, especially those that are treatable. In many cases, a definite underlying cause is not identified. Approximately 35% to 40% of DCM cases are thus determined to be idiopathic after a negative workup for secondary causes.(3) This has traditionally been termed idiopathic dilated cardiomyopathy (IDC).

Clustering of idiopathic DCM within families has been reported, leading to the conclusion that at least some cases of DCM have a genetic basis. Familial DCM is diagnosed when 2 closely related family members have IDC in the absence of underlying causes. Penetrance of familial DCM is variable and age-dependent, often leading to lack of appreciation of the familial component.

Treatment of DCM is similar to other causes of heart failure. This includes medications to reduce fluid overload and relieve strain on the heart, and lifestyle modifications such as salt restriction. Patients with clinically significant arrhythmias may also be treated with antiarrhythmic medications, pacemaker and/or an automatic implantable cardiac defibrillator (AICD). AICD placement for primary prevention may also be performed if criteria for low ejection fraction and/or other clinical symptoms are present. DCM that is end stage can be treated with cardiac transplantation.

Genetic DCM

Genetic DCM has been proposed as a newer classification that includes both familial dilated cardiomyopathy and some cases of sporadic idiopathic dilated cardiomyopathy. The percent of patients with sporadic DCM that have a genetic basis is not well characterized. The majority of pathologic mutations are inherited in an autosomal dominant fashion, but some autosomal recessive, X-linked, and mitochondrial patterns of inheritance are also present.(4)

In general, genotype-phenotype correlations are either not present or not well characterized. There have been some purported correlations between certain genetic mutations and the presence of arrhythmias. For example, patients with conduction system disease and/or a family history of sudden cardiac death may be more likely to have mutations in the LMNA, SCN5A, and DES.(1)

There may be interactions between genetic and environmental factors that lead to the clinical manifestations of DCM. A genetic variant may not in itself be sufficient to cause DCM, but may predispose to the development of DCM in the presence of environmental factors such as nutritional deficiencies or viral infections. (2) It has also been suggested that DCM genetics may be more complex than simply single-gene mutations, with low penetrance variants that are common in the population contributing to a cumulative risk of DCM that includes both genetic and environmental factors.

Genetic Testing for DCM

Approximately 30% to 40% of patients who are referred for genetic testing will have a pathologic mutation identified.(4) Pathologic mutations associated with DCM have been identified in more than 40 genes of various types and locations. The most common genes involved are those that code for titin (TTN), myosin heavy chain (MYH7), troponin T (TNNT2), and alpha-tropomysin (TPM1). These four genes account for approximately 30% of pathologic mutations identified in cohorts of patients with DCM.(4) A high proportion of the identified mutations are rare, or novel, variants, thus creating challenges in assigning the pathogenicity of discovered variants.(2)

Genetic testing can be performed on any of a number of candidate genes individually or collectively. Because of the large number of potential mutations associated with DCM and the infrequent nature of most mutations, panel testing is frequently offered. Some examples of genetic panels for DCM that are commercially available are provided in Table 1.

Table 1. Commercially Available Genetic Panels for Dilated Cardiomyopathy


Panel Name

No. of Genes Tested

Testing Method

Ambry Genetics

DCM panel


Next-gen sequencing


DCM sequencing panel

Cardiomyopathies Del/Dup Panel



Next-gen sequencing



DCM panel

Conduction disease-DCM Panel



Sanger sequencing

Sanger sequencing

Partners Healthcare

DCM panel


Next-gen sequencing

Baylor COM

DCM panel


Sanger sequencing

DCM: Dilated cardiomyopathy

Some individuals with DCM will be found to have more than 1 pathologic DCM mutation.(1) The frequency of multiple mutations is not certain, as is the clinical significance.

Regulatory Status

No U.S. Food and Drug Administration‒cleared genotyping tests were identified. The available commercial genetic tests for epilepsy are offered as laboratory-developed tests. Clinical laboratories may develop and validate tests in-house (“home-brew”) and market them as a laboratory service; such tests must meet the general regulatory standards of the Clinical Laboratory Improvement Act.


Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply.

Benefit Application



This policy was created in January 2014 with review of the literature through December 15, 2013.

The evaluation of a genetic test focuses on 3 main principles: (1) analytic validity (the technical accuracy of the test in detecting a mutation that is present or in excluding a mutation that is absent); (2) clinical validity (the diagnostic performance of the test [sensitivity, specificity, positive and negative predictive values] in detecting clinical disease); and (3) clinical utility (how the results of the diagnostic test will be used to change management of the patient and whether these changes in management lead to clinically important improvements in health outcomes).

Analytic Validity

Commercially available genetic testing for dilated cardiomyopathy (DCM) involves a variety of methods such as chip-based oligonucleotide hybridization, direct sequencing of protein-coding portions and flanking regions of targeted exons, and next-generation sequencing. The analytic validity is highest for direct sequencing, approaching 100%. For other methods of genetic testing, the analytic validity may be lower and less precisely defined. For genomic hybridization and next-generation sequencing, the analytic sensitivity is in the range of 95% to 99%.

Clinical Validity

There are numerous studies that evaluate the percentage of patients with clinically diagnosed DCM who have pathologic mutations. These studies vary in the genes examined and methods used to detect mutations. The most common type of study describes the presence of 1 type of mutation in probands with DCM or family members of the proband.(5-10)

There are fewer studies that evaluate cohorts of patients with DCM for the presence of any known DCM mutation. Hershberger et al examined cohort of 313 patients with DCM, 183 with familial DCM and 130 with sporadic DCM.(11) There were a total of 31 unique variants identified in 36 probands (11.5%). The 6 genes evaluated and the frequencies of mutations identified were MYH7 (4.2%), TNNT2 (2.9%), SCN5A (2.6%), TCAP (1.0%), LDB3 (1.0%), and CSRP3 (0.3%). However, only 11 of the 31 probands had variants that were judged to be probably pathologic. The remainder were judged to be possibly pathologic (n=21) or unlikely pathologic (n=4).

In 2011, Millat et al examined a cohort of 105 unrelated patients with DCM.(12) Sixty-four individuals had familial DCM and 41 had sporadic DCM. All the coding exons and intronic junctions of the MYH7, LMNA, TNNT2, TNNI3, and RBM20 genes were examined by high-resolution melting and direct sequencing. Pathologic mutations were found in 19% (20/105) of individuals. Ten mutations were novel variants and 9 were previously described variants.

In 2012, Lakdawala studied 264 unrelated adult and pediatric individuals with DCM, approximately half of whom had familial disease.(13) Ten genes (MYH7, TNNT2, TNNI3, TPM1, MYBPC3, ACTC, LMNA, PLN, TAZ, LDB3) were analyzed by direct sequence analysis. A total of 40 unique pathologic mutations were identified in 17.4% (46/264) of individuals with DCM. The genes with the most frequent mutations were MYH7 (6.6%), LMNA (5.3%), and TNNT2 (3.7%). Variants of uncertain significance were identified in an additional 10.6% (28/264) of individuals.

Use of next-generation sequencing technology may lead to higher sensitivity for detecting mutations.(14-16) Herman et al analyzed TTN mutations in 312 individuals with a clinical diagnosis of DCM.(14) This study also included control groups of 231 individuals with hypertrophic cardiomyopathy and 249 individuals without heart disease. Next-generation sequencing techniques were used to identify variants on the TTN gene, and these variants were further characterized by polymerase chain reaction‒ and dideoxy-sequencing; restriction digestion, and gel electrophoresis; or RNA-sequencing.

Mutations in the TTN gene that were judged to be pathologic were identified in 67/312 (21.5%) individuals with DCM. There were 72 unique mutations identified, 25 nonsense, 23 frameshift, 23 splicing, and 1 large insertion. TTN mutations were found in 3/231 (1%) of patients with hypertrophic cardiomyopathy and 7/249 (3%) of patients without heart disease, which was a significantly lower frequency compared with patients with DCM (p<0.001).

Whole-exome sequencing of 4 genes was used by Hirtle-Lewis et al as part of a strategy to identify and classify genetic variants associated with DCM.(17) The population consisted of 96 patients with idiopathic DCM treated at 1 clinic in Canada. The 4 genes examined were LMNA, TNNT2, TCAP, and PLN, all of which had been previously examined by direct-sequence analysis without any pathologic variants identified. A total of 11 variants were identified, 7 of which were novel variants. Two of the variants were judged to have a high probability of causing disease, 4 were judged to be variants of unknown significance, with the remainder being benign variants.

Section Summary

The clinical validity of genetic testing for DCM is relatively low. The clinical sensitivity is uncertain, but likely to be less than 40%. New mutations continue to be discovered, and next-generation sequencing methods may accelerate gene discovery. The clinical specificity is also uncertain, but variants thought to pathologic have been reported in some patients without cardiomyopathy. The use of next-generation sequencing may decrease clinical specificity if it identifies more variants of uncertain significance.

Clinical Utility

The potential clinical utility of genetic testing for DCM includes confirmation of the diagnosis, evaluating whether there is a genetic cause in an individual with idiopathic DCM, and/or evaluating whether a close relative has inherited a disease-causing mutation that is known to be present in the family.

In order to demonstrate clinical utility, the results of genetic testing should be associated with some changes in management that lead to improved outcomes. Changes in management could include initiation of therapy in a patient in whom the diagnosis is confirmed, and/or changes in screening or surveillance for at-risk family members.

Confirming the diagnosis of DCM. Genetic testing could have utility if it was able to confirm the diagnosis of DCM when the diagnosis cannot be made clinically, or if it were used to confirm a diagnosis earlier than would otherwise be possible without genetic testing, and if earlier diagnosis led to management changes that improve outcomes.

The diagnosis of DCM is made on clinical grounds, requiring the presence of left ventricular enlargement and evidence of systolic dysfunction. The presence or absence of a genetic mutation will not alter the clinical diagnosis of DCM. Genetic testing may have an influence on the diagnostic workup for the underlying etiology of DCM. In patients with a likely familial component, genetic testing may improve the efficiency of workup by avoiding other tests for secondary causes of DCM that are likely to be negative. In patients with sporadic forms of DCM, testing for secondary causes will likely still precede genetic testing, so that genetic testing will not influence the diagnostic workup.

Treatment for DCM does not vary according to whether a genetic mutation is present. While there is general agreement that early treatment for DCM is optimal, there are no trials that demonstrate improved outcomes with presymptomatic treatment compared with waiting until the onset of symptoms. If early treatment is based primarily on genetic testing, then the additional concerns of false positive and false negative tests need to be considered.

Predictive testing. In family members of patients with DCM, genetic testing can be used to determine if a known pathologic mutation has been inherited. There are several issues in predictive testing for DCM that create challenges in establishing clinical utility.

This first requires confidence that the mutation identified in the proband is causative of DCM. If this is not the case, then genetic testing may provide misleading information. Because of the high number of novel mutations and variants of unknown significance identified in DCM, the confidence that a mutation is causative of the disorder is less than for some other conditions.

The uncertain penetrance and variable clinical expression also needs to be considered in determining the utility of predictive testing. Because of the heterogeneity in clinical expression, it may not be possible to adequately counsel an asymptomatic patient on the likelihood of developing DCM even when an inherited mutation has been identified.

Predictive testing may lead to changes in screening and surveillance, particularly for patients who test negative in whom surveillance might be discontinued. However, it is not certain that this approach will lead to improved outcomes. For example, a proband may be identified with a variant that is possibly pathologic. A close family member may test negative for that variant and be falsely reassured that they are not at risk for DCM when they still may harbor another undiscovered mutation.

Section Summary

Clinical utility of genetic testing for DCM has not been established. Genetic testing is not likely to alter the diagnosis of DCM, which is based on clinical factors. For some patients with likely familial disease, the diagnostic workup may be altered, but the extent of change and the impact on outcomes is unclear. Predictive testing may have some role in testing at-risk family members but is currently limited by the low clinical validity of testing, and heterogeneity in penetrance and clinical expression of disease.


Dilated cardiomyopathy (DCM) is a disorder of cardiac muscle that leads to progressive left ventricular enlargement, heart failure, and/or cardiac arrhythmias. A subset of DCM is caused by genetic mutations. Genetic forms of DCM are heterogeneous in the types of genetic mutations, clinical expression, and hereditability.

Many genetic mutations on more than 40 different genes have been associated with DCM. This remains an active area of research, and it is likely that many more mutations will be identified in the future. The analytic validity of genetic testing for DCM is expected to be high when testing is performed by direct sequencing or next-generation sequencing. In contrast, the clinical validity is not high. The percent of patients with idiopathic DCM who have a genetic mutation (clinical sensitivity) is relatively low, in the range of 30% to 40%. The clinical specificity of DCM-associated mutations is not known, but DCM-associated mutations in the some genes have been reported in 1% to 3% of patients without DCM.

The clinical utility of genetic testing for DCM is uncertain. For a patient who is diagnosed with idiopathic DCM, the presence of a genetic mutation will not change treatment or prognosis. For an individual at risk due to genetic DCM in the family, genetic testing can identify whether the mutation has been inherited. However, it is uncertain how knowledge of a mutation will improve outcomes for an asymptomatic individual. Early treatment based on a genetic diagnosis is unproven. The uncertain accuracy of predictive testing makes it uncertain whether changes in management will improve outcomes.

Because of the low clinical validity and uncertain clinical utility, genetic testing for dilated cardiomyopathy is considered investigational in all situations.

Practice Guidelines and Position Statements

The Heart Rhythm Society (HRS) and the European Hearth Rhythm Association issued joint guidelines in 2011 on genetic testing for cardiac channelopathies and cardiomyopathies.(18) These guidelines contained the following recommendations on genetic testing for DCM:

Class I recommendations

  • Comprehensive or targeted (LMNA and SCN5A) DCM genetic testing is recommended for patients with DCM and significant cardiac conduction disease (i.e., first-, second-, or third-degree heart block) and/or a family history of premature unexpected sudden death.
  • Mutation-specific testing is recommended for family members and appropriate relatives following the identification of a DCM-causative mutation in the index case

Class IIa recommendations

  • Genetic testing can be useful for patients with familial DCM to confirm the diagnosis, to recognize those who are highest risk of arrhythmia and syndromic features, to facilitate cascade screening within the family, and to help with family planning.

The Heart Failure Society of America (HFSA) published a practice guideline in 2009 on the Genetic Evaluation of Cardiomyopathy.(19) The following recommendations for genetic testing for cardiomyopathy (including DCM) were made:

  • Evaluation, genetic counseling, and genetic testing of cardiomyopathy patients are complex processes. Referral to centers expert in genetic evaluation and family-based management should be considered (Level of Evidence B).
  • Genetic testing should be considered for the one most clearly affected person in a family to facilitate screening and management.
  • Genetic and family counseling is recommended for all patients and families with cardiomyopathy (Level of Evidence A).

Medicare National Coverage

There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.


  1. Hersheberger RE M, A. Dilated Cardiomyopathy Overview. GeneReviews 2013. Available online at: Last accessed February 7, 2014.
  2. Piran S, Liu P, Morales A et al. Where genome meets phenome: rationale for integrating genetic and protein biomarkers in the diagnosis and management of dilated cardiomyopathy and heart failure. J Am Coll Cardiol 2012; 60(4):283-9.
  3. Hershberger RE, Morales A, Siegfried JD. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med 2010; 12(11):655-67.
  4. Lakdawala NK, Winterfield JR, Funke BH. Dilated cardiomyopathy. Circ Arrhythm Electrophysiol 2013; 6(1):228-37.
  5. Brodsky GL, Muntoni F, Miocic S et al. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation 2000; 101(5):473-6.
  6. MacLeod HM, Culley MR, Huber JM et al. Lamin A/C truncation in dilated cardiomyopathy with conduction disease. BMC Med Genet 2003; 4:4.
  7. Olson TM, Michels VV, Thibodeau SN et al. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998; 280(5364):750-2.
  8. Sylvius N, Duboscq-Bidot L, Bouchier C et al. Mutational analysis of the beta- and delta-sarcoglycan genes in a large number of patients with familial and sporadic dilated cardiomyopathy. Am J Med Genet A 2003; 120A(1):8-12.
  9. Taylor MR, Slavov D, Ku L et al. Prevalence of desmin mutations in dilated cardiomyopathy. Circulation 2007; 115(10):1244-51.
  10. Villard E, Duboscq-Bidot L, Charron P et al. Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene. Eur Heart J 2005; 26(8):794-803.
  11. Hershberger RE, Parks SB, Kushner JD et al. Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. Clin Transl Sci 2008; 1(1):21-6.
  12. Millat G, Bouvagnet P, Chevalier P et al. Clinical and mutational spectrum in a cohort of 105 unrelated patients with dilated cardiomyopathy. Eur J Med Genet 2011; 54(6):e570-5.
  13. Lakdawala NK, Funke BH, Baxter S et al. Genetic testing for dilated cardiomyopathy in clinical practice. J Card Fail 2012; 18(4):296-303.
  14. Herman DS, Lam L, Taylor MR et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012; 366(7):619-28.
  15. Norton N, Li D, Rieder MJ et al. Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. Am J Hum Genet 2011; 88(3):273-82.
  16. Theis JL, Sharpe KM, Matsumoto ME et al. Homozygosity mapping and exome sequencing reveal GATAD1 mutation in autosomal recessive dilated cardiomyopathy. Circ Cardiovasc Genet 2011; 4(6):585-94.
  17. Hirtle-Lewis M, Desbiens K, Ruel I et al. The genetics of dilated cardiomyopathy: a prioritized candidate gene study of LMNA, TNNT2, TCAP, and PLN. Clin Cardiol 2013; 36(10):628-33.
  18. Ackerman MJ, Priori SG, Willems S et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8(8):1308-39.
  19. Hershberger RE, Lindenfeld J, Mestroni L et al. Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline. J Card Fail 2009; 15(2):83-97.







Molecular pathology procedure, Level 4 (e.g., analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons)



Molecular pathology procedure, Level 5 (e.g., analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis)



Molecular pathology procedure, Level 7 (e.g., analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia)



Molecular pathology procedure, Level 8 (e.g., analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform)

(effective 10/01/15)


Dilated cardiomyopathy







New Policy. New policy developed with literature review through December 15, 2013. Genetic testing for dilated cardiomyopathy is considered investigational for all indications.


Update Related Policies. Remove 12.04.91.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA).
©2014 Premera All Rights Reserved.